Alberto Bardelli
#119,162
Most Influential Person Now
Researcher
Alberto Bardelli's AcademicInfluence.com Rankings
Alberto Bardellibiology Degrees
Biology
#7173
World Rank
#10050
Historical Rank
Biotechnology
#83
World Rank
#85
Historical Rank
Genetics
#690
World Rank
#777
Historical Rank
Molecular Biology
#819
World Rank
#839
Historical Rank
Download Badge
Biology
Alberto Bardelli's Degrees
- PhD Biomedical Sciences University of Milan
- Masters Biotechnology University of Milan
- Bachelors Biology University of Milan
Similar Degrees You Can Earn
Why Is Alberto Bardelli Influential?
(Suggest an Edit or Addition)According to Wikipedia, Alberto Bardelli is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology, University of Turin and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.
Alberto Bardelli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- High Frequency of Mutations of the PIK3CA Gene in Human Cancers (2004) (3428)
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016) (2368)
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. (2010) (1968)
- International network of cancer genome projects (2010) (1839)
- Liquid biopsies: genotyping circulating tumor DNA. (2014) (1705)
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR (2012) (1701)
- Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. (2008) (1616)
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer (2012) (1611)
- Liquid biopsy: monitoring cancer-genetics in the blood (2013) (1396)
- Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status (2002) (1288)
- Integrating liquid biopsies into the management of cancer (2017) (1235)
- A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family (1994) (1010)
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. (2005) (968)
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (823)
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) (794)
- PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. (2009) (764)
- Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. (2010) (714)
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma (2014) (691)
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition (2016) (677)
- Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. (2010) (665)
- Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. (1991) (660)
- A Phosphatase Associated with Metastasis of Colorectal Cancer (2001) (656)
- Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (2007) (645)
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. (2016) (639)
- Colorectal cancer: Mutations in a signalling pathway (2005) (578)
- Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. (2013) (560)
- Toward understanding and exploiting tumor heterogeneity (2015) (557)
- Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer (2009) (543)
- Mutational Analysis of the Tyrosine Phosphatome in Colorectal Cancers (2004) (533)
- Induction of epithelial tubules by growth factor HGF depends on the STAT pathway (1998) (532)
- Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (472)
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth (2017) (397)
- Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. (2014) (394)
- Liquid Biopsies, What We Do Not Know (Yet). (2017) (371)
- IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors (2009) (367)
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. (2010) (356)
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer (2010) (340)
- HGF receptor associates with the anti‐apoptotic protein BAG‐1 and prevents cell death. (1996) (335)
- Mutational analysis of the tyrosine kinome in colorectal cancers. (2003) (330)
- Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. (2017) (328)
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. (2016) (319)
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade (2018) (287)
- Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. (2014) (276)
- The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma (2010) (275)
- Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer (2009) (275)
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (271)
- Early‐onset colorectal cancer in young individuals (2018) (267)
- Biological Activation of pro-HGF (Hepatocyte Growth Factor) by Urokinase Is Controlled by a Stoichiometric Reaction (*) (1995) (261)
- Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer (2014) (232)
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets (2015) (230)
- Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. (2015) (218)
- Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). (1994) (214)
- Adaptive mutability of colorectal cancers in response to targeted therapies (2019) (211)
- Alterations in Vascular Gene Expression in Invasive Breast Carcinoma (2004) (210)
- PRL-3 expression in metastatic cancers. (2003) (209)
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo (2018) (209)
- The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. (1995) (203)
- Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer (2015) (203)
- AKT1E17K in human solid tumours (2008) (202)
- The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma (1996) (200)
- Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. (2004) (198)
- The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death (2016) (189)
- Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers (2003) (188)
- TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. (2019) (184)
- Carcinogen-specific induction of genetic instability (2001) (184)
- A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor (1993) (182)
- Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas (2012) (181)
- The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. (2014) (173)
- KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy (2013) (168)
- Specific Uncoupling of GRB2 from the Met Receptor (1996) (164)
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas (2010) (164)
- Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. (2007) (160)
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer (2011) (158)
- Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer (2017) (156)
- Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET (2013) (154)
- Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer (2016) (149)
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer (2018) (147)
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer. (2020) (145)
- Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer. (2015) (144)
- PRL-3 Phosphatase Is Implicated in Ovarian Cancer Growth (2005) (141)
- Tumor Evolution as a Therapeutic Target. (2017) (141)
- Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists (1999) (140)
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study) (2009) (140)
- PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. (2014) (137)
- Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential (1997) (132)
- Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer (2016) (131)
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer (2015) (127)
- Acquired resistance to EGFR‐targeted therapies in colorectal cancer (2014) (118)
- Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. (2014) (111)
- Identifying tumor origin using a gene expression-based classification map. (2003) (109)
- High-dose vitamin C enhances cancer immunotherapy (2020) (108)
- Targeted therapies: how personal should we go? (2012) (108)
- RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. (2014) (108)
- Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses (2008) (104)
- Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. (2018) (104)
- Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers (2015) (100)
- Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. (2015) (98)
- Novel mutation in the ATP‐binding site of the MET oncogene tyrosine kinase in a HPRCC family (1999) (96)
- Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients (2015) (96)
- Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth. (1998) (96)
- How liquid biopsies can change clinical practice in oncology. (2019) (95)
- A point mutation in the MET oncogene abrogates metastasis without affecting transformation. (1997) (93)
- Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (2017) (91)
- PIK3CA cancer mutations display gender and tissue specificity patterns (2008) (90)
- Different point mutations in the met oncogene elicit distinct biological properties (2000) (87)
- Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. (2016) (86)
- TGFα and Amphiregulin Paracrine Network Promotes Resistance to EGFR Blockade in Colorectal Cancer Cells (2014) (86)
- Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance (2014) (85)
- Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. (2016) (83)
- Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer (2018) (80)
- How liquid biopsies can change clinical practice in oncology. (2019) (80)
- Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis (1999) (79)
- Genetic analysis of the kinome and phosphatome in cancer (2005) (79)
- Exploring the links between cancer and placenta development (2018) (78)
- MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. (2016) (76)
- TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations (2019) (76)
- Consensus on precision medicine for metastatic cancers: a report from the MAP conference. (2016) (75)
- Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial (2018) (74)
- A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility (2016) (74)
- MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations (2016) (72)
- SMAC/Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs (NSAIDs) in colon cancer cells. (2004) (71)
- HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. (2019) (70)
- CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2016) (70)
- Expression and functional regulation of myoglobin in epithelial cancers. (2009) (70)
- Exploiting DNA repair defects in colorectal cancer (2019) (70)
- Autophosphorylation promotes complex formation of recombinant hepatocyte growth factor receptor with cytoplasmic effectors containing SH2 domains. (1992) (69)
- Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial (2020) (68)
- Precision oncology in metastatic colorectal cancer — from biology to medicine (2021) (66)
- The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type (2010) (65)
- The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers. (2018) (64)
- RET fusions in a small subset of advanced colorectal cancers at risk of being neglected (2018) (64)
- A Peptide Representing the Carboxyl-terminal Tail of the Met Receptor Inhibits Kinase Activity and Invasive Growth* (1999) (64)
- MET mutations in cancers of unknown primary origin (CUPs) (2011) (64)
- PIK3CA-activating mutations and chemotherapy sensitivity in stage II–III breast cancer (2008) (63)
- Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET (1999) (62)
- The road to resistance: EGFR mutation and cetuximab (2012) (62)
- Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). (2011) (62)
- Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer (2017) (62)
- Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. (2001) (61)
- Trastuzumab and lapatinib in HER2-amplified metastatic colorectal cancer patients (mCRC): The HERACLES trial. (2015) (60)
- A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin (2019) (60)
- Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. (2019) (57)
- Blood circulating tumor DNA for non‐invasive genotyping of colon cancer patients (2016) (56)
- Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2 (1997) (54)
- The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer (2016) (54)
- Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. (2005) (54)
- Mutational profiling of kinases in glioblastoma (2014) (53)
- Mutational Profiling of Kinases in Human Tumours of Pancreatic Origin Identifies Candidate Cancer Genes in Ductal and Ampulla of Vater Carcinomas (2010) (53)
- Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. (2018) (52)
- Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. (1994) (52)
- Active PI3K Pathway Causes an Invasive Phenotype Which Can Be Reversed or Promoted by Blocking the Pathway at Divergent Nodes (2012) (52)
- Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases (2017) (51)
- Mutational Profile of GNAQ Q209 in Human Tumors (2009) (51)
- Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers (2011) (49)
- Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions (2017) (48)
- Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. (1994) (48)
- Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia (2011) (47)
- Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes (2009) (47)
- Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers (2017) (46)
- Mutational analysis of gene families in human cancer. (2005) (46)
- p21 (WAF1/CIP1) Mediates the Growth Response to TGF-b in Human Epithelial Cells (2004) (45)
- Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (2018) (45)
- Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases (2019) (44)
- Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model (2015) (44)
- The DNA Damage Response pathway as a land of therapeutic opportunities for colorectal cancer. (2020) (43)
- Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published series (2008) (42)
- Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer (2017) (42)
- Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. (2019) (42)
- Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. (2020) (41)
- Molecular profiling of the “plexinome” in melanoma and pancreatic cancer (2009) (41)
- Recommendations for mutational analysis of EGFR in lung carcinoma. (2010) (39)
- Exposure to the tobacco smoke constituent 4-aminobiphenyl induces chromosomal instability in human cancer cells. (2007) (38)
- Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. (2021) (38)
- Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer (2019) (37)
- Knock-in of oncogenic Kras does not transform mouse somatic cells but triggers a transcriptional response that classifies human cancers. (2007) (36)
- Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer (2020) (36)
- Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor Met. (1998) (36)
- Absence of AKT1 Mutations in Glioblastoma (2009) (35)
- "Invasive-growth" signaling by the Met/HGF receptor: the hereditary renal carcinoma connection. (1997) (35)
- Preclinical models for precision oncology. (2018) (34)
- KRAS Mutations Testing in Colorectal Carcinoma Patients in Italy: From Guidelines to External Quality Assessment (2011) (34)
- Somatic alterations as the basis for resistance to targeted therapies (2014) (34)
- Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. (2016) (33)
- Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). (2009) (33)
- Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance (2017) (33)
- Computational drugs repositioning identifies inhibitors of oncogenic PI3K/AKT/P70S6K-dependent pathways among FDA-approved compounds (2016) (33)
- Evolving neoantigen profiles in colorectal cancers with DNA repair defects (2019) (32)
- Genetic targeting of the kinase activity of the Met receptor in cancer cells (2007) (32)
- Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients (2017) (32)
- Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (2010) (32)
- Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. (2010) (31)
- The combination of IDH 1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH 1 or MGMT alone (2014) (30)
- Liquid Biopsies for Monitoring Temporal Genomic Heterogeneity in Breast and Colon Cancers (2017) (30)
- Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy. (2021) (29)
- Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer. (2005) (29)
- PRL-3: A phosphatase for metastasis? (2004) (28)
- Restoring PUMA induction overcomes KRAS-mediated resistance to anti-EGFR antibodies in colorectal cancer (2018) (27)
- Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor (2017) (27)
- Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial (2022) (27)
- METPRC mutations in the ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential (1999) (26)
- Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case (2018) (26)
- Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer (2017) (25)
- Identification of cancer genes by mutational profiling of tumor genomes (2005) (25)
- Clonally expanded EOMES+ Tr1-like cells in primary and metastatic tumors are associated with disease progression (2021) (25)
- HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: The HERACLES-RESCUE trial. (2016) (25)
- Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers (2021) (24)
- Towards a cancer mission in Horizon Europe: recommendations (2020) (24)
- Lemur tyrosine kinase 2 (LMTK2) is a determinant of cell sensitivity to apoptosis by regulating the levels of the BCL2 family members. (2017) (24)
- Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. (2017) (24)
- Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ (2021) (24)
- High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib (2019) (23)
- Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. (2016) (22)
- Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? (2013) (22)
- Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunities. (2020) (21)
- Climbing RAS, the everest of oncogenes. (2014) (21)
- Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer (2014) (21)
- BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors (2013) (21)
- Liquid biopsies to evaluate early therapeutic response in colorectal cancer. (2015) (21)
- Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients (2019) (21)
- Targeted Knock‐in of the Polymorphism rs61764370 Does Not Affect KRAS Expression but Reduces let‐7 Levels (2014) (20)
- Abstract CT005: Final results of the HERACLES trial in HER2-amplified colorectal cancer (2017) (20)
- TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors. (2020) (19)
- The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation. (2021) (19)
- Therapeutic dual inhibition of HER2 pathway for metastatic colorectal cancer (mCRC): The HERACLES trial. (2015) (19)
- CD4 T cell dependent rejection of beta 2 microglobulin null mismatch repair deficient tumors. (2021) (19)
- Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer (2017) (18)
- A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology. (2019) (18)
- Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial (2019) (17)
- Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. (2013) (17)
- Scatter factor receptors are key players in a unique multistep program leading to invasive growth. (1997) (17)
- Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects (2011) (15)
- Liquid biopsies to monitor and direct cancer treatment in colorectal cancer (2022) (15)
- KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. (2009) (15)
- Coronavirus lockdown: What I learnt when I shut my cancer lab in 48 hours (2020) (15)
- Minimal Residual Disease in Breast Cancer: In Blood Veritas (2014) (15)
- Advances in Brief Activating Mutations of the Noonan Syndrome-Associated SHP 2 / PTPN 11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia (2004) (14)
- Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies (2018) (14)
- Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients (2022) (14)
- The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. (2020) (13)
- Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway (2015) (13)
- Kinase mutations in cancer: chinks in the enemy's armour? (2006) (13)
- Two main mutational processes operate in the absence of DNA mismatch repair. (2020) (13)
- D01*Final Results of the HERACLES trial in HER2 amplified colorectal cancer (2016) (12)
- Review: Peering through a keyhole: liquid biopsy in primary and metastatic central nervous system tumours (2019) (11)
- Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor (1998) (11)
- Genomic landscapes of cancers: prospects for targeted therapies. (2007) (11)
- Dual anti-HER2 treatment of patients with HER2-positive metastatic colorectal cancer: The HERACLES trial (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification). (2013) (11)
- Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. (2017) (11)
- A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells (2022) (11)
- resistance to EGFR blockade in colorectal cancer cells (2014) (11)
- RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer (2020) (11)
- The status of tumor mutational burden and immunotherapy (2022) (11)
- Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial. (2019) (11)
- Efficacy of Sym 004 in PatientsWithMetastatic Colorectal CancerWith Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNAAnalyses A Phase 2 Randomized Clinical Trial (2018) (10)
- Integrated approaches for precision oncology in colorectal cancer: the more you know, the better. (2021) (10)
- Activation of β-Catenin by Oncogenic PIK3CA and EGFR Promotes Resistance to Glucose Deprivation by Inducing a Strong Antioxidant Response (2012) (10)
- Medical research: Personalized test tracks cancer relapse (2017) (10)
- Isogenic mutant human cells: A new tool for personalized cancer medicine (2010) (10)
- MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours (2016) (9)
- Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine–resistant cancer cells (2005) (9)
- PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in breast cancer (2010) (8)
- Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases (2022) (8)
- Does early metastatic seeding occur in colorectal cancer? (2019) (8)
- EGFR Amplification in Metastatic Colorectal Cancer. (2021) (8)
- Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients (2016) (8)
- Abstract A089: Exploiting clonal evolution and liquid biopsy to overcome resistance to anti-EGFR treatment in metastatic colorectal cancer: the CHRONOS trial (2018) (7)
- Modeling Tumor Progression by the Sequential Introduction of Genetic Alterations into the Genome of Human Normal Cells (2013) (7)
- Role of Kras mutations in predicting response and survival in irinotecan-refiractory patients treated with cetuximab and irinotecan for metastatic colorectal cancer: Analysis of 281 patients with individual data (2008) (7)
- Inactivation of DNA repair—prospects for boosting cancer immune surveillance (2018) (7)
- Cancer Therapy : Preclinical Tivantinib ( ARQ 197 ) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET (2013) (6)
- Systematic liquid biopsy identifies novel and heterogeneous mechanisms of acquired resistance in gastrointestinal (GI) cancer patients. (2017) (6)
- MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients. (2015) (6)
- Liquid biopsy, a paradigm shift in oncology: what interventional radiologists should know (2020) (6)
- KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients (2009) (6)
- Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation (2016) (6)
- Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. (2019) (6)
- Broccoli, PTEN deletion and prostate cancer: where is the link? (2010) (6)
- Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways (2021) (5)
- Liquid biopsies for residual disease and recurrence. (2021) (5)
- Amplification of the MET receptor to drive resistance to anti-EGFR therapies in colorectal cancer. (2013) (5)
- 247 ORAL BRAF V600E confers resistance to cetuximab or panitumumab in metastatic colorectal cancer (2008) (5)
- Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2017) (4)
- Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study (2022) (4)
- Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids (2021) (4)
- The cancer genome (2011) (4)
- Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. (2021) (4)
- Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines (2022) (4)
- Tracking colorectal cancer evolution in time and space. (2017) (4)
- Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance (2022) (4)
- DNA damage response and repair genes in advanced bone and soft tissue sarcomas: An 8-gene signature as a candidate predictive biomarker of response to trabectedin and olaparib combination (2022) (3)
- Epidermal Growth Factor Receptor Antibody Therapies − Anti Impairs the Response of Metastatic Colorectal Cancers to Oncogenic Activation of the RAS / RAF Signaling Pathway (2007) (3)
- P2.08 Emergence of Kras Mutations and Acquired Resistance to Anti Egfr Therapy in Colorectal Cancer (2012) (3)
- Abstract 4114: Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in FGFR2 fusion-positive cholangiocarcinoma patients (2017) (3)
- Homeobox B 9 mediates resistance to anti-VEGF therapy in colorectal cancer patients (3)
- Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer (2022) (3)
- The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway (2022) (3)
- Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. (2017) (3)
- Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer (2016) (3)
- Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing? (2013) (3)
- Abstract 5723: Inactivation of DNA repair triggers neoantigen generation and impairs tumor growth (2018) (3)
- Erratum: Alterations in vascular gene expression in invasive breast carcinoma (Cancer Research (November 1, 2004) 64, 1 (7857-7866)) (2004) (3)
- Phase II study of temozolomide (TMZ) in metastatic colorectal cancer (mCRC) patients molecularly selected by MGMT promoter hypermethylation. (2015) (3)
- Understanding how kinase-targeted therapies work (2008) (3)
- Diablo-dependent apoptosis induced by nonsteroidal antiinflammatory drugs ( NSAIDs ) in colon cancer cells (2004) (2)
- T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models (2021) (2)
- Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2018) (2)
- Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (2)
- Companion Diagnostics and Cancer Biomarkers BRAF V 600 E Is a Determinant of Sensitivity to Proteasome Inhibitors (2013) (2)
- Digital PCR quanti fi cation of MGMT methylation re fi nes prediction of clinical bene fi t from alkylating agents in glioblastoma and metastatic colorectal cancer (2015) (2)
- Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC). (2021) (2)
- 478OEfficacy and safety of Sym004 in refractory metastatic colorectal cancer with acquired resistance to anti-EGFR therapy: Results of a randomized phase II study (RP2S) (2017) (2)
- Correlation of PIK3CA mutation-associated gene expression signature (PIK3CA-GS) with deactivation of the PI3K pathway and with prognosis within the luminal-B ER+ breast cancers. (2009) (2)
- Clinicopathological characteristics and HER2 status in metastatic colorectal cancer patients: Results of a diagnostic model development study. (2018) (2)
- Somatic mutations of EGFR signal transducers and expression of tumor suppressor PTEN in biliary tract carcinoma (2007) (2)
- Abstract A173: Potent anti-tumor activity of entrectinib in patient-derived models harboring oncogenic gene rearrangements of NTRKs (2015) (2)
- Concomitant blockade of EGFR and MEK overcomes acquired resistance to anti-EGFR therapy in colorectal cancer cells and patients’ avatars. (2014) (2)
- Tracking the genomic evolution of breast cancer metastasis (2010) (2)
- Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. (2019) (2)
- Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial (2020) (1)
- ResearchThe analysis of PIK 3 CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type (2015) (1)
- Erratum to: Integrated molecular dissection of the epidermal growth factor receptor (EGFR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (2012) (1)
- Abstract C94: Heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer are sensitive to concomitant inhibition of EGFR and MEK. (2013) (1)
- Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features (2022) (1)
- Abstract 3151: Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusions (2017) (1)
- Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours (2016) (1)
- Failure is not final: ctDNA-guided rechallenge therapy in colorectal cancer. (2019) (1)
- Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials. (2010) (1)
- Abstract PR01: Acquisition of resistance to anti-EGFR therapy drives genomic heterogeneity and lesion-specific responses in colorectal cancer (2015) (1)
- Mutational profiling of kinases in glioblastoma (2014) (1)
- Clinical and molecular landscape of metastatic colorectal cancer (mCRC) harboring ALK, ROS1, or NTRK 1, 2, 3 (NTRKs) rearrangements. (2017) (1)
- Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations (2016) (1)
- Processing Techniques For Expanding Spread Experiments Applied to the Crustal CROP Project (1994) (1)
- Corrigendum to Preclinical models for precision oncology. BBACAN 1870/2 (2018) 239-246. (2019) (1)
- Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. (2023) (1)
- Reply to E. Hawkes et al (2010) (1)
- Abstract B229: Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer (2009) (1)
- 2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC) (2015) (1)
- Abstract PR13: Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth (2017) (1)
- PIK3CA mutation-associated gene expression signature correlates with deactivation of the PI3K pathway and predicts benefit to endocrine therapy in high-risk ER+ (luminal B) breast cancers (BC). (2009) (1)
- 123PGenotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004 (2017) (1)
- Abstract 2848: Radiographic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer (2018) (1)
- Abstract 878: Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer (2016) (1)
- 99INLIQUID BIOPSIES: GENOTYPING CIRCULATING TUMOUR DNA IN COLORECTAL CANCER. (2014) (1)
- Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (2022) (1)
- Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. (2020) (1)
- Individual KRAS mutations modulate response to targeted agents in colorectal cancer. (2011) (1)
- 166 Acquired Resistance to Anti EGFR Therapy in Colorectal Cancer and Paracrine Protection by KRAS Mutated Cells (2012) (1)
- Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient (2023) (1)
- Abstract PL06-01: Liquid biopsies to monitor response and resistance to targeted therapies. (2013) (1)
- Evolving neoantigen profiles in colorectal cancers with DNA repair defects (2019) (0)
- Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT) (2023) (0)
- Drug-induced colorectal cancer persister cells show increased mutation rate (2021) (0)
- Therapeutics , Targets , and Chemical Biology Mixed Lineage Kinase MLK 4 Is Activated in Colorectal Cancers Where It Synergistically Cooperates with Activated RAS Signaling in Driving Tumorigenesis (2013) (0)
- Abstract PL04-03: Heterogeneity, drug resistance, and clonal evolution in colorectal cancers (2016) (0)
- Abstract B049: Characterizing and targeting RET fusions-positive metastatic colorectal cancer (mCRC) (2018) (0)
- Raise and decline of KRAS mutant clones in colorectal cancers (CRCs) treated with multiple rounds of anti-EGFR antibodies. (2015) (0)
- K-Ras and B-Raf mutations and anti-EGFR antibody treatment (2008) (0)
- MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer author ( s ) list : (0)
- A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours (2018) (0)
- UvA-DARE ( Digital Academic Repository ) Absence of AKT 1 Mutations in Glioblastoma (2009) (0)
- NEDD 8 pathway inhibition is effective in preclinical models of poorly differentiated , clinically aggressive colorectal cancer (2016) (0)
- Abstract 2611: The NEDD8 pathway as a therapeutic target in HER2-amplified colorectal cancer (2022) (0)
- moto genesis peptide antagonists of cellular mitogenesis and, and their therapeutic use (1997) (0)
- Abstract IA022: Exploiting immune surveillance to target colorectal cancer evolution and mutability (2022) (0)
- Abstract A70: Isogenic K-Ras mutant cancer cells: A novel platform for drug profiling. (2011) (0)
- 59 Understanding the genetic basis of resistance to EGFR targeted therapies to personalize colorectal cancer treatment (2009) (0)
- Identification of the transduction pathways mediating the cellular responses to the hepatocyte growth factor/scatter factor. (1996) (0)
- TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors (2019) (0)
- Abstract 3834: Tracking CAD-ALK gene translocation in urine and plasma of a colorectal cancer patient treated with ALK blockade (2017) (0)
- Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study. (2016) (0)
- Signal transducers as molecular targets for cancer therapy (1997) (0)
- Loss of the heme exporter FLVCR1a impairs mitochondrial functionality: a new approach against colorectal cancer (2018) (0)
- This is the author's final version of the contribution published as: Di Nicolantonio F;Bardelli A. Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?. CLINICAL CANCER (0)
- Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds (2007) (0)
- IDH1R132 mutations occur frequently in high-grade gliomas but not in other solid tumors (2009) (0)
- 112P Clinicopathological characterization of MTAP-altered metastatic gastrointestinal tumors (2022) (0)
- Abstract 616: Blood-based molecular landscapes of resistance to EGFR blockade in colorectal cancer patients (2015) (0)
- Abstract 2861: PUMA induction by p73 mediates response and resistance of colorectal cancer to anti-EGFR antibody therapy (2018) (0)
- 54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients (2014) (0)
- Mutational profiling of glioblastoma (2009) (0)
- Abstract 6262: Emergence of tumor mismatch repair deficiency and increased mutational burden in blood and tissue of metastatic colorectal cancer patients treated with temozolomide (2022) (0)
- PO-050 A molecularly annotated platform of pdx-derived cell lines mirrors the genomic landscape of colorectal cancer (2018) (0)
- PO-332 Genomic landscapes, neoantigen profiles and biological impact of MLH1 inactivation in cancer cells (2018) (0)
- Loss of A XIN 1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO 3 fusions (2016) (0)
- S29Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies - THE CORNUCOPIA STUDY (2016) (0)
- Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance (2014) (0)
- Abstract 1935: The NEDD8 and EGFR pathways are independent therapeutic targets in colorectal cancer (2020) (0)
- Abstract B110: Heterogeneous genetic alterations emerge during acquired resistance to anti-EGFR therapy in colorectal cancer. (2013) (0)
- Preclinical testing of NEDD8 and proteasome inhbitors for a treatment-refractory, metastatic high-grade mucinous colorectal cancer patient (2018) (0)
- Abstract 3588: Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer (2015) (0)
- Abstract LB058: A transcriptome-wide gene expression outlier analysis pinpoints therapeutic vulnerabilities in colorectal cancer (2023) (0)
- Abstract IA18: Cancer evolution as a therapeutic target (2018) (0)
- The heme exporter FLVCR1a modulates the tricarboxylic acid cycle: a new target in colorectal cancer (2018) (0)
- Abstract LB-257: Liquid biopsy versus tissue biopsy to assess acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (0)
- The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/β-catenin pathway (2022) (0)
- Description of a novel JAK3-P132A mutation in Acute Megakaryoblastic Leukemia and demonstration of previously reported JAK3 mutations in normal subjects (2014) (0)
- Abstract B069: Temozolomide drives mismatch repair deficiency and fosters neoantigen generation in tumor cells (2019) (0)
- Abstract C68: Endogenous expression of an oncogenic PI3K mutation leads to epithelial‐mesenchymal transition (EMT) and invasiveness (2009) (0)
- 373. Use of Lentiviral and Adeno-Associated Vectors for Targeted Gene Inactivation in Human Cancer Cells (2005) (0)
- SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo (2018) (0)
- Abstract 3265: Homeobox B9 (HOXB9) sustains anti-VEGF treatment resistance in gastrointestinal tumors (2016) (0)
- Abstract 4034: ALKBH3 deficiency and liability to alkylating agents in CRC models (2022) (0)
- The FUNNEL: A molecular multiplex triage for precision medicine in metastatic colorectal cancer. (2016) (0)
- Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening (2013) (0)
- Corrigendum: Case report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (2023) (0)
- Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. CANCER (0)
- Metabolic adaptation in colorectal cancer: heme export is required for the modulation of the tricarboxylic acid cycle. (2019) (0)
- Abstract IA18: Inactivation of DNA repair to improve immune surveillance (2019) (0)
- Abstract 2148: MM-151 elicits broad and unique inhibition of cells harboring EGFR extracellular domain mutations — results of multiscale experiments with genome-edited cell lines (2016) (0)
- Abstract 5900: Tolerance to colibactin correlates with response to chemotherapeutic agents in colorectal cancer (2023) (0)
- Abstract 2743: Accumulation of predicted neoantigens by MMR deficiency triggered by temozolomide treatment of human colorectal cancer (2018) (0)
- Abstract LB-213: NEDD8 pathway inhibition is effective in preclinical models of poorly differentiated, clinically aggressive colorectal cancer (2016) (0)
- Abstract 3403: Conservation of colorectal cancer cell-intrisinc transcriptional traits in pairedin vitro/in vivocellular models (2018) (0)
- Mutation enrichment next-generation sequencing for quantitative detection of KRAS mutations in urine cell-free DNA from patients with advanced colorectal and other cancers. (2017) (0)
- Mixed lineage kinase 4 (MLK4) is mutationally activated in colorectal cancers and its inactivation impairs the growth of RAS-driven tumors (0)
- Inactivation of DNA repair—prospects for boosting cancer immune surveillance (2018) (0)
- Abstract 916: The molecular landscape of colorectal cancer cell lines unveils clinically actionable targets (2015) (0)
- Abstract 2913: Emergence ofRASorEGFRmutant clones affects duration of response to EGFR blockade in colorectal cancers (2017) (0)
- Abstract 230: Modeling tumor progression and identifying genotype-drug interactions by the sequential introduction of cancer mutations into the genome of human normal cells (2011) (0)
- Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy? (2013) (0)
- Funding: Roche Disclosure: J. Bennouna: Advisory Board for Roche, Boehringer Ingelheim, (2017) (0)
- PO-019 PTPN11 is a therapeutic target in KRAS mutant lung cancer (2018) (0)
- PLXNB1 mutations in human cancer (2009) (0)
- Abstract 1397: Synthetic lethality screenings highlight colorectal cancer vulnerability to concomitant blockade of the NEDD8 and EGFR pathways (2021) (0)
- Abstract 583: Colorectal cancer cell lines recapitulate molecular and pharmacological features of clinical samples (2015) (0)
- Abstract LB-299: A comprehensive platform of patient-derived xenografts and matched cell lines mirrors the genomic landscape of colorectal cancer (2019) (0)
- PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study (2021) (0)
- Abstract IA2: Mechanisms of resistance to anti EGFR therapies in colorectal cancers (2012) (0)
- 370P Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial (2022) (0)
- Abstract IA22: Clonal evolution and drug resistance in colorectal cancers: The EGFR-RAS signaling pathway (2017) (0)
- Abstract SY21-03: Cancer evolution as a therapeutic target (2017) (0)
- Personalized Medicine and Imaging Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer (2014) (0)
- Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer (2016) (0)
- RET rearrangements define an uncommon molecular subtype of metastatic colorectal cancer (mCRC). (2017) (0)
- IN THE SPOTLIGHT Climbing RAS, the Everest of Oncogenes (2014) (0)
- Abstract CT214: AlfaOmega- a master protocol empowering precision research in colorectal cancer (2019) (0)
- HGFreceptorassociates withtheanti-apoptotic protein BAG-1andpreventscelldeath (1996) (0)
- Abstract 16: Landscape and outcome of TRK fusion-positive Cancers (2020) (0)
- 24 The Role of KRAS/BRAF Mutations on Response and Resistance to Anti EGFR Therapies in Colorectal Tumors (2012) (0)
- Abstract CT215: Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer (2019) (0)
- Author Correction: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features (2023) (0)
- glioblastomas display improved survival and reduced NADP + -dependent IDH activity ex vivo (2009) (0)
- Classification Map Identifying Tumor Origin Using a Gene Expression-based Updated Version (2003) (0)
- Cancer Therapy : Preclinical Toll-like Receptor 9 Agonist IMOCooperateswithCetuximab in KRas Mutant Colorectal and Pancreatic Cancers (2011) (0)
- UvA-DARE ( Digital Academic Repository ) Mutational profiling of glioblastoma (2009) (0)
- Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies (2018) (0)
- Classifies Human Cancers Somatic Cells But Triggers a Transcriptional Response that Does Not Transform Mouse Kras Knockin of Oncogenic (2007) (0)
- Abstract 1692:KRAS-mediated therapeutic resistance abrogates immunogenic cell death in colorectal cancer cells (2017) (0)
- Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations (2015) (0)
- Abstract 5419: A unique pattern of heterogeneous MMR protein expression in colorectal cancer unveils different degrees of tumor mutational burden and distinct tumor microenvironment features (2022) (0)
- Bcl-xL and association with apoptosis following KRASG12C inhibition in KRASG12C mutant colorectal cancer. (2022) (0)
- Abstract IA13: Tracking and targeting colorectal cancer evolution (2020) (0)
- Abstract 5680: TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors (2020) (0)
- Abstract 1843: Primary and acquired resistance to HERs inhibition in colorectal cancer cells: All HERs go to RAS (2014) (0)
- Precision oncology for KRASG12C-mutant colorectal cancer. (2023) (0)
- Abstract LB-75: Blood-based molecular detection of acquired resistance to anti-EGFR therapies in colorectal cancer patients. (2013) (0)
- Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case (2019) (0)
- Absence of AKT 1 mutations in glioblastoma (2017) (0)
- Abstract B11: Whole-exome sequencing analysis of urine transrenal tumor DNA in metastatic colorectal cancer patients (2020) (0)
- B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients (0)
- 23: Mutations and acquired resistance in colorectal cancer (2014) (0)
- Abstract 2613: A modified Luria-Delbrück assay allows quantification of colorectal cancer persister cells’ mutation rate (2022) (0)
- Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers (2019) (0)
- Abstract 6402: The effects of cytotoxic chemotherapy on colorectal cancer immunogenicity (2023) (0)
- Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies (2011) (0)
- SP-0453 Targeting DNA repair to improve immunesurveillance and restrict cancer growth (2019) (0)
- Abstract C131: HSP27 is necessary in cells showing oncogene hyper-activation. (2013) (0)
- EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES (2009) (0)
- The heme exporter FLVCR1A modulates cellular redox status and mitochondrial metabolism: implication in colorectal cancer (2017) (0)
- Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer (2022) (0)
- Abstract 1593: Genetic and pharmacological modulation of DNA mismatch repair promotes immune surveillance in murine colorectal cancer (2022) (0)
- Abstract CN02-03: Heterogeneity, drug resistance, and clonal dynamics in colorectal cancers (2015) (0)
This paper list is powered by the following services:
Other Resources About Alberto Bardelli
What Schools Are Affiliated With Alberto Bardelli?
Alberto Bardelli is affiliated with the following schools:
